NPORT-EX 2 edgar.htm
Schedule of Investments(a)
Invesco Nasdaq Biotechnology ETF (IBBQ)
May 31, 2022
(Unaudited)
  Shares   Value
Common Stocks & Other Equity Interests-100.00%
Biotechnology-78.68%
4D Molecular Therapeutics, Inc.(b)
  816   $6,193
89bio, Inc.(b)
  496   1,493
Abcam PLC, ADR (United Kingdom)(b)
  630   9,362
AC Immune S.A. (Switzerland)(b)(c)
  2,001   6,283
Acadia Pharmaceuticals, Inc.(b)(c)
  4,038   65,214
Achilles Therapeutics PLC, ADR (United Kingdom)
  974   2,435
Acumen Pharmaceuticals, Inc.(b)
  990   3,505
Adaptimmune Therapeutics PLC, ADR(b)
  3,455   4,975
Adicet Bio, Inc.(b)
  978   11,560
ADMA Biologics, Inc.(b)(c)
  4,918   10,082
Adverum Biotechnologies, Inc.(b)
  2,391   2,145
Aeglea BioTherapeutics, Inc.(b)
  1,235   1,951
Aerovate Therapeutics, Inc.(b)(c)
  602   7,314
Affimed N.V. (Germany)(b)
  3,719   11,529
Agios Pharmaceuticals, Inc.(b)
  1,370   26,674
Akebia Therapeutics, Inc.(b)
  4,391   1,624
Akero Therapeutics, Inc.(b)
  879   7,595
Akouos, Inc.(b)(c)
  849   2,649
Alaunos Therapeutics, Inc.(b)
  5,223   2,704
Alector, Inc.(b)(c)
  2,068   18,323
Aligos Therapeutics, Inc.(b)(c)
  977   1,260
Alkermes PLC(b)
  4,074   121,609
Allakos, Inc.(b)
  1,365   4,095
Allogene Therapeutics, Inc.(b)(c)
  3,596   28,516
Allovir, Inc.(b)
  1,642   6,355
Alnylam Pharmaceuticals, Inc.(b)
  3,018   379,664
Alpine Immune Sciences, Inc.(b)
  730   6,789
Altimmune, Inc.(b)
  976   4,939
ALX Oncology Holdings, Inc.(b)
  1,023   7,846
Amarin Corp. PLC, ADR (Ireland)(b)
  9,920   14,384
Amgen, Inc.
  8,981   2,305,782
Amicus Therapeutics, Inc.(b)
  7,042   53,660
AnaptysBio, Inc.(b)(c)
  691   13,122
Anavex Life Sciences Corp.(b)(c)
  1,917   17,464
Annexon, Inc.(b)
  956   3,002
Apellis Pharmaceuticals, Inc.(b)
  2,465   102,174
Applied Molecular Transport, Inc.(b)(c)
  964   3,191
Applied Therapeutics, Inc.(b)
  637   917
Arbutus Biopharma Corp.(b)
  3,396   8,252
Arcturus Therapeutics Holdings, Inc.(b)(c)
  668   13,280
Arcutis Biotherapeutics, Inc.(b)(c)
  1,266   26,434
Argenx SE, ADR (Netherlands)(b)
  693   214,345
Arrowhead Pharmaceuticals, Inc.(b)
  2,649   88,371
Ascendis Pharma A/S, ADR (Denmark)(b)
  1,394   117,807
Atara Biotherapeutics, Inc.(b)
  2,353   12,236
Athenex, Inc.(b)
  2,649   1,268
Aurinia Pharmaceuticals, Inc. (Canada)(b)
  3,563   40,191
Autolus Therapeutics PLC, ADR (United Kingdom)
  1,449   3,970
Avidity Biosciences, Inc.(b)(c)
  1,186   16,521
Avrobio, Inc.(b)
  1,041   1,012
Beam Therapeutics, Inc.(b)(c)
  1,719   60,474
BeiGene Ltd., ADR (China)(b)(c)
  1,248   171,251
BELLUS Health, Inc. (Canada)(b)
  2,677   21,255
Bicycle Therapeutics PLC, ADR (United Kingdom)(b)
  641   10,250
BioAtla, Inc.(b)(c)
  903   2,176
BioCryst Pharmaceuticals, Inc.(b)(c)
  4,631   43,115
Biogen, Inc.(b)
  3,684   736,800
BioMarin Pharmaceutical, Inc.(b)
  4,619   347,025
  Shares   Value
Biotechnology-(continued)
Biomea Fusion, Inc.(b)(c)
  723   $3,969
BioNTech SE, ADR (Germany)(b)
  2,213   361,516
Black Diamond Therapeutics, Inc.(b)(c)
  882   1,491
Bluebird Bio, Inc.(b)(c)
  1,760   5,632
Blueprint Medicines Corp.(b)
  1,482   81,510
Bolt Biotherapeutics, Inc.(b)
  902   1,533
Bridgebio Pharma, Inc.(b)(c)
  3,717   25,387
Brooklyn ImmunoTherapeutics, Inc.(b)(c)
  1,266   849
C4 Therapeutics, Inc.(b)(c)
  1,217   8,835
Cabaletta Bio, Inc.(b)
  722   924
Candel Therapeutics, Inc.(b)
  724   2,729
Caribou Biosciences, Inc.(b)
  1,512   12,595
Cellectis S.A., ADR (France)(b)
  497   1,799
Centessa Pharmaceuticals PLC, ADR(b)
  471   2,120
Century Therapeutics, Inc.(b)(c)
  1,370   11,905
ChemoCentryx, Inc.(b)
  1,758   39,151
Chimerix, Inc.(b)
  2,189   4,115
Chinook Therapeutics, Inc.(b)(c)
  1,326   20,129
Clovis Oncology, Inc.(b)(c)
  3,580   2,489
Codiak Biosciences, Inc.(b)(c)
  574   1,601
Cogent Biosciences, Inc.(b)
  1,162   5,357
Coherus Biosciences, Inc.(b)(c)
  1,950   14,313
Compass Pathways PLC, ADR (United Kingdom)(b)
  574   5,218
Connect Biopharma Holdings Ltd., ADR (China)(b)
  1,203   962
Cortexyme, Inc.(b)
  734   1,901
Corvus Pharmaceuticals, Inc.(b)
  1,134   1,168
Crinetics Pharmaceuticals, Inc.(b)
  1,344   22,512
CRISPR Therapeutics AG (Switzerland)(b)(c)
  1,944   112,849
Cullinan Oncology, Inc.(b)
  1,090   11,652
CureVac N.V. (Germany)(b)(c)
  4,704   88,435
Curis, Inc.(b)(c)
  2,308   1,764
Cyteir Therapeutics, Inc.(b)(c)
  866   1,645
Cytokinetics, Inc.(b)
  2,129   84,947
CytomX Therapeutics, Inc.(b)
  1,613   2,597
Day One Biopharmaceuticals, Inc.(b)(c)
  1,563   9,722
Decibel Therapeutics, Inc.(b)
  612   1,346
Deciphera Pharmaceuticals, Inc.(b)
  1,667   18,070
Denali Therapeutics, Inc.(b)(c)
  3,096   75,202
Design Therapeutics, Inc.(b)(c)
  1,400   17,472
Dyne Therapeutics, Inc.(b)
  1,300   6,253
Eagle Pharmaceuticals, Inc.(b)(c)
  313   14,617
Editas Medicine, Inc.(b)(c)
  1,711   19,488
Eiger BioPharmaceuticals, Inc.(b)(c)
  1,086   7,537
Enanta Pharmaceuticals, Inc.(b)
  518   20,684
Epizyme, Inc.(b)
  3,960   1,663
Erasca, Inc.(b)(c)
  3,049   16,526
Evelo Biosciences, Inc.(b)(c)
  1,335   2,804
Exelixis, Inc.(b)
  8,038   147,337
Fate Therapeutics, Inc.(b)(c)
  2,427   56,064
FibroGen, Inc.(b)(c)
  2,348   23,104
Forma Therapeutics Holdings, Inc.(b)
  1,201   6,834
Frequency Therapeutics, Inc.(b)
  851   953
G1 Therapeutics, Inc.(b)(c)
  1,086   5,278
Galapagos N.V., ADR (Belgium)(b)
  322   17,713
Gamida Cell Ltd. (Israel)(b)
  1,485   3,237
Generation Bio Co.(b)
  1,440   8,093
Genmab A/S, ADR (Denmark)(b)
  1,088   32,912
Geron Corp.(b)
  9,444   13,033
Gilead Sciences, Inc.
  30,983   2,009,248
Global Blood Therapeutics, Inc.(b)
  1,626   40,552
Gossamer Bio., Inc.(b)(c)
  1,926   13,578
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
May 31, 2022
(Unaudited)
  Shares   Value
Biotechnology-(continued)
Gracell Biotechnologies, Inc., ADR (China)(b)
  1,484   $4,882
Graphite Bio, Inc.(b)(c)
  1,464   3,440
Grifols S.A., ADR (Spain)
  2,904   37,404
Gritstone bio, Inc.(b)
  1,722   3,478
Halozyme Therapeutics, Inc.(b)
  3,469   159,505
Harpoon Therapeutics, Inc.(b)(c)
  789   1,625
Homology Medicines, Inc.(b)(c)
  1,391   2,045
Horizon Therapeutics PLC(b)
  5,694   510,695
Humacyte, Inc.(b)(c)
  2,599   14,113
Icosavax, Inc.(b)(c)
  976   6,627
Ideaya Biosciences, Inc.(b)(c)
  959   10,693
IGM Biosciences, Inc.(b)
  658   11,041
I-Mab, ADR (China)(b)(c)
  1,241   10,797
Imago Biosciences, Inc.(b)(c)
  835   13,494
Immuneering Corp., Class A(b)(c)
  631   2,827
Immunic, Inc.(b)
  706   4,377
ImmunityBio, Inc.(b)(c)
  9,997   37,589
ImmunoGen, Inc.(b)
  5,537   20,265
Immunovant, Inc.(b)
  2,928   12,415
Impel Pharmaceuticals Inc.(b)(c)
  567   3,907
Incyte Corp.(b)
  5,561   422,024
Infinity Pharmaceuticals, Inc.(b)
  2,152   1,447
Inhibrx, Inc.(b)(c)
  975   12,743
Inovio Pharmaceuticals, Inc.(b)(c)
  5,282   9,877
Insmed, Inc.(b)
  2,977   56,027
Instil Bio, Inc.(b)(c)
  3,246   19,492
Intellia Therapeutics, Inc.(b)
  1,873   86,420
Intercept Pharmaceuticals, Inc.(b)(c)
  727   13,159
Ionis Pharmaceuticals, Inc.(b)
  3,564   130,157
Iovance Biotherapeutics, Inc.(b)
  3,955   26,696
Ironwood Pharmaceuticals, Inc.(b)(c)
  4,008   45,170
iTeos Therapeutics, Inc.(b)
  887   15,523
IVERIC bio, Inc.(b)(c)
  2,907   30,349
Janux Therapeutics, Inc.(b)(c)
  1,052   11,709
Jounce Therapeutics, Inc.(b)
  1,292   5,000
KalVista Pharmaceuticals, Inc.(b)
  603   5,361
Kamada Ltd. (Israel)(b)
  1,123   5,065
Karuna Therapeutics, Inc.(b)(c)
  747   77,927
Karyopharm Therapeutics, Inc.(b)(c)
  1,899   11,926
Keros Therapeutics, Inc.(b)
  580   19,604
Kezar Life Sciences, Inc.(b)(c)
  1,424   7,191
Kiniksa Pharmaceuticals Ltd., Class A(b)
  850   6,511
Kinnate Biopharma, Inc.(b)
  1,091   8,663
Kodiak Sciences, Inc.(b)
  1,306   9,455
Kronos Bio, Inc.(b)(c)
  1,428   5,312
Krystal Biotech, Inc.(b)
  634   37,330
Kura Oncology, Inc.(b)
  1,679   22,096
Kymera Therapeutics, Inc.(b)
  1,306   18,637
Larimar Therapeutics, Inc.(b)
  410   1,058
Leap Therapeutics, Inc.(b)
  2,139   2,310
Legend Biotech Corp., ADR(b)
  1,344   56,838
Lexicon Pharmaceuticals, Inc.(b)
  3,745   6,629
Ligand Pharmaceuticals, Inc.(b)(c)
  413   36,720
Lyell Immunopharma, Inc.(b)(c)
  6,038   24,997
MacroGenics, Inc.(b)
  1,545   5,361
Madrigal Pharmaceuticals, Inc.(b)(c)
  414   27,485
Magenta Therapeutics, Inc.(b)
  1,470   1,705
MannKind Corp.(b)(c)
  6,328   26,451
MeiraGTx Holdings PLC(b)(c)
  1,113   9,338
Mereo Biopharma Group PLC, ADR (United Kingdom)
  2,931   1,481
Mersana Therapeutics, Inc.(b)
  2,461   8,220
  Shares   Value
Biotechnology-(continued)
Merus N.V. (Netherlands)(b)
  1,084   $20,119
Mirati Therapeutics, Inc.(b)
  1,395   54,628
Mirum Pharmaceuticals, Inc.(b)(c)
  772   18,057
Moderna, Inc.(b)
  9,955   1,446,760
Molecular Templates, Inc.(b)(c)
  1,374   1,358
Monte Rosa Therapeutics, Inc.(b)(c)
  1,174   9,087
Morphic Holding, Inc.(b)(c)
  941   22,057
Mustang Bio, Inc.(b)
  2,258   1,457
Myriad Genetics, Inc.(b)(c)
  2,009   38,653
Neoleukin Therapeutics, Inc.(b)
  1,028   1,028
Neurocrine Biosciences, Inc.(b)
  2,392   223,628
NextCure, Inc.(b)
  707   2,757
Nkarta, Inc.(b)(c)
  1,208   17,431
Novavax, Inc.(b)(c)
  1,900   105,127
Nurix Therapeutics, Inc.(b)(c)
  1,122   11,321
Nuvalent, Inc., Class A(b)(c)
  1,074   9,516
ObsEva S.A. (Switzerland)(c)
  2,071   3,749
Olema Pharmaceuticals, Inc.(b)
  987   2,823
Omega Therapeutics, Inc.(b)(c)
  1,214   2,756
Oncocyte Corp.(b)
  2,251   2,431
Oncorus, Inc.(b)
  629   749
ORIC Pharmaceuticals, Inc.(b)
  986   3,293
Ovid therapeutics, Inc.(b)
  1,713   2,895
Oyster Point Pharma, Inc.(b)
  676   2,657
Passage Bio, Inc.(b)
  1,354   2,437
PMV Pharmaceuticals, Inc.(b)(c)
  1,141   13,418
Poseida Therapeutics, Inc.(b)
  1,580   3,587
Praxis Precision Medicines, Inc.(b)(c)
  1,144   9,495
Precigen, Inc.(b)
  5,197   6,964
Precision BioSciences, Inc.(b)
  1,487   2,498
Prelude Therapeutics, Inc.(b)(c)
  1,196   5,023
Prometheus Biosciences, Inc.(b)
  972   25,330
ProQR Therapeutics N.V. (Netherlands)(b)
  1,740   1,148
Protagonist Therapeutics, Inc.(b)
  1,208   10,582
Prothena Corp. PLC (Ireland)(b)(c)
  1,179   32,104
PTC Therapeutics, Inc.(b)
  1,797   52,778
Puma Biotechnology, Inc.(b)
  998   1,936
Radius Health, Inc.(b)(c)
  1,200   7,596
Rallybio Corp.(b)
  816   11,098
RAPT Therapeutics, Inc.(b)(c)
  739   10,878
Recursion Pharmaceuticals, Inc., Class A(b)(c)
  4,002   24,492
Regeneron Pharmaceuticals, Inc.(b)
  2,636   1,752,255
REGENXBIO, Inc.(b)
  1,088   22,892
Relay Therapeutics, Inc.(b)(c)
  2,735   44,526
Repare Therapeutics, Inc. (Canada)(b)
  1,055   9,685
Replimune Group, Inc.(b)
  1,195   17,363
REVOLUTION Medicines, Inc.(b)(c)
  1,858   31,549
Rhythm Pharmaceuticals, Inc.(b)
  1,263   4,345
Rigel Pharmaceuticals, Inc.(b)
  4,297   7,778
Rocket Pharmaceuticals, Inc.(b)(c)
  1,617   19,161
Rubius Therapeutics, Inc.(b)
  2,261   2,487
SAB Biotherapeutics, Inc.(c)
  1,038   2,034
Sage Therapeutics, Inc.(b)
  1,478   46,217
Sana Biotechnology, Inc.(b)(c)
  4,757   24,403
Sangamo Therapeutics, Inc.(b)(c)
  3,668   13,388
Sarepta Therapeutics, Inc.(b)(c)
  2,186   159,185
Scholar Rock Holding Corp.(b)(c)
  882   4,428
Seagen, Inc.(b)
  4,609   625,349
Selecta Biosciences, Inc.(b)
  2,935   2,589
Sensei Biotherapeutics, Inc.(b)
  747   1,419
Sera Prognostics, Inc., Class A(b)(c)
  723   1,005
Seres Therapeutics, Inc.(b)
  2,314   7,173
 
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
May 31, 2022
(Unaudited)
  Shares   Value
Biotechnology-(continued)
Sesen Bio, Inc.(b)
  4,823   $2,956
Shattuck Labs, Inc.(b)(c)
  1,071   3,063
Silverback Therapeutics, Inc.(b)(c)
  860   3,001
Solid Biosciences, Inc.(b)
  2,667   1,520
Spectrum Pharmaceuticals, Inc.(b)
  3,954   2,955
Spero Therapeutics, Inc.(b)
  822   970
SpringWorks Therapeutics, Inc.(b)
  1,235   23,391
Stoke Therapeutics, Inc.(b)
  932   11,287
Summit Therapeutics, Inc.(b)
  2,465   3,278
Surface Oncology, Inc.(b)(c)
  1,126   2,083
Sutro Biopharma, Inc.(b)
  1,170   5,090
Syndax Pharmaceuticals, Inc.(b)
  1,331   21,962
Syros Pharmaceuticals, Inc.(b)
  1,509   1,240
Talaris Therapeutics, Inc.(b)
  1,044   8,989
Taysha Gene Therapies, Inc.(b)
  959   2,445
TCR2 Therapeutics, Inc.(b)
  910   2,111
Tenaya Therapeutics, Inc.(b)
  1,042   6,981
Tonix Pharmaceuticals Holding Corp.(b)(c)
  390   952
Travere Therapeutics, Inc.(b)
  1,593   37,133
Turning Point Therapeutics, Inc.(b)
  1,244   44,000
Twist Bioscience Corp.(b)
  1,413   48,099
Ultragenyx Pharmaceutical, Inc.(b)
  1,739   81,559
uniQure N.V. (Netherlands)(b)(c)
  1,173   16,844
United Therapeutics Corp.(b)
  1,133   260,975
UroGen Pharma Ltd.(b)(c)
  576   3,064
Vanda Pharmaceuticals, Inc.(b)
  1,407   13,831
Vaxcyte, Inc.(b)
  1,419   34,042
Veracyte, Inc.(b)
  1,793   31,521
Verastem, Inc.(b)
  4,583   5,866
Vertex Pharmaceuticals, Inc.(b)
  6,289   1,689,540
Verve Therapeutics, Inc.(b)(c)
  1,199   18,177
Vir Biotechnology, Inc.(b)(c)
  3,331   85,973
Viracta Therapeutics, Inc.(b)(c)
  903   1,914
Vor BioPharma, Inc.(b)(c)
  946   3,983
Werewolf Therapeutics, Inc.(b)(c)
  663   2,513
Xencor, Inc.(b)(c)
  1,487   33,205
Xenon Pharmaceuticals, Inc. (Canada)(b)
  1,302   34,308
Y-mAbs Therapeutics, Inc.(b)(c)
  1,089   13,547
Zai Lab Ltd., ADR (China)(b)(c)
  1,779   51,769
Zentalis Pharmaceuticals, Inc.(b)
  1,432   34,526
        18,625,609
Health Care Equipment & Supplies-0.95%
Bioventus, Inc., Class A(b)(c)
  1,489   14,711
Novocure Ltd.(b)(c)
  2,618   210,435
        225,146
Health Care Providers & Services-0.62%
23andMe Holding Co., Class A(b)(c)
  5,305   15,915
Castle Biosciences, Inc.(b)
  640   14,253
Guardant Health, Inc.(b)(c)
  2,565   105,114
PetIQ, Inc.(b)(c)
  727   12,475
        147,757
Life Sciences Tools & Services-5.94%
AbCellera Biologics, Inc. (Canada)(b)(c)
  7,144   54,437
Absci Corp.(b)(c)
  2,336   8,526
Adaptive Biotechnologies Corp.(b)(c)
  3,561   27,847
Alpha Teknova, Inc.(b)(c)
  692   5,294
Codex DNA, Inc.(b)(c)
  723   2,878
Codexis, Inc.(b)
  1,636   17,472
Compugen Ltd. (Israel)(b)(c)
  2,177   4,027
Harvard Bioscience, Inc.(b)(c)
  997   3,649
  Shares   Value
Life Sciences Tools & Services-(continued)
Illumina, Inc.(b)
  3,114   $745,741
Maravai LifeSciences Holdings, Inc., Class A(b)
  3,306   102,982
MaxCyte, Inc.(b)
  2,523   11,631
Medpace Holdings, Inc.(b)
  885   126,767
NanoString Technologies, Inc.(b)(c)
  1,149   17,970
Nautilus Biotechnology, Inc.(b)(c)
  3,120   11,419
Pacific Biosciences of California, Inc.(b)(c)
  5,557   31,286
Personalis, Inc.(b)
  1,128   4,467
Quantum-Si, Inc.(b)(c)
  2,960   12,580
Rapid Micro Biosystems, Inc., Class A(b)(c)
  862   4,319
Seer, Inc.(b)(c)
  1,440   12,787
Singular Genomics Systems, Inc.(b)(c)
  1,818   5,909
Syneos Health, Inc.(b)
  2,612   193,001
        1,404,989
Pharmaceuticals-13.81%
Aclaris Therapeutics, Inc.(b)(c)
  1,544   19,748
Aerie Pharmaceuticals, Inc.(b)
  1,205   6,242
Amphastar Pharmaceuticals, Inc.(b)
  1,199   44,531
Aquestive Therapeutics, Inc.(b)(c)
  985   979
Arvinas, Inc.(b)
  1,337   55,740
AstraZeneca PLC, ADR (United Kingdom)
  14,754   980,846
ATAI Life Sciences N.V. (Germany)(b)
  4,025   16,020
Atea Pharmaceuticals, Inc.(b)
  2,094   16,501
Athira Pharma, Inc.(b)
  948   8,608
Avadel Pharmaceuticals PLC, ADR(c)
  1,462   3,231
Axsome Therapeutics, Inc.(b)(c)
  960   24,000
Cara Therapeutics, Inc.(b)(c)
  1,335   11,107
Clearside Biomedical, Inc.(b)
  1,484   1,929
Collegium Pharmaceutical, Inc.(b)
  830   12,965
Cymabay Therapeutics, Inc.(b)
  2,124   4,163
Edgewise Therapeutics, Inc.(b)
  1,231   7,694
Endo International PLC(b)
  5,882   3,104
Esperion Therapeutics, Inc.(b)(c)
  1,592   9,074
Evolus, Inc.(b)(c)
  1,398   18,034
EyePoint Pharmaceuticals, Inc.(b)
  851   8,212
Fulcrum Therapeutics, Inc.(b)
  1,020   7,262
Harmony Biosciences Holdings, Inc.(b)(c)
  1,472   64,179
Harrow Health, Inc.(b)
  684   4,945
Hutchmed China Ltd., ADR (China)(b)
  1,449   15,243
Ikena Oncology, Inc.(b)(c)
  905   3,530
Innoviva, Inc.(b)
  1,744   26,456
Intra-Cellular Therapies, Inc.(b)
  2,331   133,799
Jazz Pharmaceuticals PLC(b)
  1,537   230,058
KemPharm, Inc.(b)(c)
  865   4,005
Landos Biopharma, Inc.(b)
  986   716
Marinus Pharmaceuticals, Inc.(b)
  931   4,515
Nektar Therapeutics, (Acquired 06/09/2021 - 03/03/2022; Cost $65,736)(b)(d)
  4,602   16,015
NGM Biopharmaceuticals, Inc.(b)(c)
  1,963   27,168
NRX Pharmaceuticals, Inc.(b)
  1,712   958
Ocular Therapeutix, Inc.(b)(c)
  1,934   6,053
Omeros Corp.(b)(c)
  1,581   3,921
Optinose, Inc.(b)(c)
  2,005   4,120
Pacira BioSciences, Inc.(b)
  1,125   71,156
Paratek Pharmaceuticals, Inc.(b)(c)
  1,230   2,325
Phathom Pharmaceuticals, Inc.(b)
  978   7,012
Phibro Animal Health Corp., Class A
  512   9,836
Pliant Therapeutics, Inc.(b)
  911   5,129
Provention Bio, Inc.(b)(c)
  1,581   6,514
Rain Therapeutics, Inc.(b)
  465   1,079
Rani Therapeutics Holdings, Inc., Class A
  620   7,068
Reata Pharmaceuticals, Inc., Class A(b)(c)
  797   22,539
 
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
May 31, 2022
(Unaudited)
  Shares   Value
Pharmaceuticals-(continued)
Redhill Biopharma Ltd., ADR (Israel)(c)
  1,326   $1,485
Relmada Therapeutics, Inc.(b)
  693   13,021
Revance Therapeutics, Inc.(b)
  1,800   24,624
Royalty Pharma PLC, Class A(c)
  10,880   447,603
Sanofi, ADR (France)
  6,951   370,141
SIGA Technologies, Inc.(c)
  1,856   20,305
Supernus Pharmaceuticals, Inc.(b)
  1,341   37,374
Terns Pharmaceuticals, Inc.(b)
  618   1,069
TherapeuticsMD, Inc.(b)(c)
  207   2,056
Theravance Biopharma, Inc.(b)
  1,873   16,445
Tricida, Inc.(b)
  1,384   11,543
Verrica Pharmaceuticals, Inc.(b)(c)
  704   1,359
Viatris, Inc.
  30,418   373,229
WaVe Life Sciences Ltd.(b)
  1,413   1,978
Xeris Biopharma Holdings, Inc.(b)(c)
  3,392   7,496
        3,268,057
TOTAL INVESTMENTS IN SECURITIES

(excluding investments purchased with cash collateral from securities on loan)-100.00%

(Cost $32,196,352)
  23,671,558
  Shares   Value
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-15.12%
Invesco Private Government Fund, 0.74%(e)(f)(g)
  1,072,094   $1,072,094
Invesco Private Prime Fund, 0.87%(e)(f)(g)
  2,506,902   2,507,152
Total Investments Purchased with Cash Collateral from Securities on Loan

(Cost $3,579,074)
  3,579,246
TOTAL INVESTMENTS IN SECURITIES-115.12%

(Cost $35,775,426)
  27,250,804
OTHER ASSETS LESS LIABILITIES-(15.12)%
  (3,578,277)
NET ASSETS-100.00%
  $23,672,527
    
 
Investment Abbreviations:
ADR -American Depositary Receipt
    
Notes to Schedule of Investments:
(a) Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b) Non-income producing security.
(c) All or a portion of this security was out on loan at May 31, 2022.
(d) Restricted security. The value of this security at May 31, 2022 represented less than 1% of the Fund’s Net Assets.
(e) Affiliated issuer. The issuer and/or the Fund is a wholly-owned subsidiary of Invesco Ltd., or is affiliated by having an investment adviser that is under common control of Invesco Ltd. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the nine months ended May 31, 2022.
    
  Value
August 31, 2021 		  Purchases
at Cost 		  Proceeds
from Sales 		  Change in
Unrealized
Appreciation 		  Realized
Gain
(Loss) 		  Value
May 31, 2022 		  Dividend
Income
Investments in Affiliated Money Market Funds:                          
Invesco Government & Agency Portfolio, Institutional Class $-   $476,316   $(476,316)   $-   $-   $-   $3
Investments Purchased with Cash Collateral from Securities on Loan:                          
Invesco Private Government Fund 262,268   8,698,819   (7,888,993)   -   -   1,072,094   1,345*
Invesco Private Prime Fund 611,959   17,272,449   (15,376,550)   172   (878)   2,507,152   3,666*
Total $874,227   $26,447,584   $(23,741,859)   $172   $(878)   $3,579,246   $5,014
    
* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.
    
(f) The rate shown is the 7-day SEC standardized yield as of May 31, 2022.
(g) The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return of the securities loaned.  
The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco PHLX Semiconductor ETF (SOXQ)
May 31, 2022
(Unaudited)
  Shares   Value
Common Stocks & Other Equity Interests-99.95%
Electronic Equipment, Instruments & Components-1.22%
II-VI Incorporated(b)
  6,761   $422,563
IPG Photonics Corp.(b)
  3,368   355,290
        777,853
Life Sciences Tools & Services-0.58%
Azenta, Inc.
  4,771   365,649
Semiconductors & Semiconductor Equipment-98.15%
Advanced Micro Devices, Inc.(b)
  45,543   4,639,010
Amkor Technology, Inc.
  15,560   318,046
Analog Devices, Inc.
  17,500   2,947,000
Applied Materials, Inc.
  20,896   2,450,892
ASML Holding N.V., New York Shares (Netherlands)
  4,216   2,429,639
Broadcom, Inc.
  9,558   5,544,883
Entegris, Inc.
  8,601   954,367
Intel Corp.
  117,747   5,230,322
KLA Corp.
  8,047   2,935,948
Lam Research Corp.
  5,006   2,603,270
Lattice Semiconductor Corp.(b)
  8,747   455,019
Marvell Technology, Inc.
  41,036   2,427,279
Microchip Technology, Inc.
  35,314   2,565,562
  Shares   Value
Semiconductors & Semiconductor Equipment-(continued)
Micron Technology, Inc.
  31,555   $2,330,021
Monolithic Power Systems, Inc.
  2,959   1,332,704
NVIDIA Corp.
  23,038   4,301,655
NXP Semiconductors N.V. (China)
  14,774   2,803,514
ON Semiconductor Corp.(b)
  27,457   1,666,091
Power Integrations, Inc.
  3,762   317,438
Qorvo, Inc.(b)
  6,886   769,510
QUALCOMM, Inc.
  32,662   4,677,852
Silicon Laboratories, Inc.(b)
  2,436   363,354
Skyworks Solutions, Inc.
  10,412   1,133,554
Taiwan Semiconductor Manufacturing Co. Ltd., ADR (Taiwan)
  26,208   2,497,622
Teradyne, Inc.
  10,306   1,126,034
Texas Instruments, Inc.
  16,530   2,921,843
Wolfspeed, Inc.(b)
  7,847   590,330
        62,332,759
TOTAL INVESTMENTS IN SECURITIES-99.95%

(Cost $70,665,072)
  63,476,261
OTHER ASSETS LESS LIABILITIES-0.05%
  33,104
NET ASSETS-100.00%
  $63,509,365
    
Investment Abbreviations:
ADR -American Depositary Receipt
    
Notes to Schedule of Investments:
(a) Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b) Non-income producing security.
Affiliated issuer. The issuer and/or the Fund is a wholly-owned subsidiary of Invesco Ltd., or is affiliated by having an investment adviser that is under common control of Invesco Ltd. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the nine months ended May 31, 2022.
    
  Value
August 31, 2021 		  Purchases
at Cost 		  Proceeds
from Sales 		  Change in
Unrealized
Appreciation 		  Realized
Gain
(Loss) 		  Value
May 31, 2022 		  Dividend
Income
Investments in Affiliated Money Market Funds:                          
Invesco Government & Agency Portfolio, Institutional Class $763   $554,808   $(555,571)   $-   $-   $-   $17
Investments Purchased with Cash Collateral from Securities on Loan:                          
Invesco Private Government Fund 105,927   2,125,412   (2,231,339)   -   -   -   80*
Invesco Private Prime Fund 247,162   4,636,709   (4,883,588)   -   (283)   -   316*
Total $353,852   $7,316,929   $(7,670,498)   $-   $(283)   $-   $413
    
* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.
The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco Solar ETF (TAN)
May 31, 2022
(Unaudited)
  Shares   Value
Common Stocks & Other Equity Interests-99.95%
Building Products-0.77%
Luoyang Glass Co. Ltd., H Shares (China)(b)(c)(d)
  11,342,147   $17,608,370
Chemicals-2.74%
Hanwha Solutions Corp. (South Korea)(c)
  1,970,191   62,185,547
Construction & Engineering-0.57%
ReneSola Ltd., ADR (China)(c)(d)
  2,723,906   12,993,031
Electrical Equipment-9.64%
Array Technologies, Inc.(c)(d)
  4,661,579   51,650,296
Shoals Technologies Group, Inc., Class A(c)(d)
  3,175,757   49,541,809
Soltec Power Holdings S.A. (Spain)(c)(d)
  2,017,380   9,366,291
Sunrun, Inc.(c)(d)
  4,144,327   108,249,821
        218,808,217
Independent Power and Renewable Electricity Producers-22.60%
Atlantica Sustainable Infrastructure PLC (Spain)
  1,889,719   61,699,325
Azure Power Global Ltd. (India)(c)(d)
  1,033,648   15,360,009
Beijing Enterprises Clean Energy Group Ltd. (China)(c)
  1,053,548,848   11,145,752
Doral Group Renewable Energy Resources Ltd. (Israel)(c)(d)
  3,434,904   11,026,930
Encavis AG (Germany)
  3,184,025   68,865,835
Energix-Renewable Energies Ltd. (Israel)(d)
  5,663,433   17,177,637
Enlight Renewable Energy Ltd. (Israel)(c)(d)
  16,960,154   30,966,752
GCL New Energy Holdings Ltd. (China)(c)
  556,435,538   11,135,023
Grenergy Renovables S.A. (Spain)(c)(d)
  364,288   15,266,333
Neoen S.A. (France)(c)(d)(e)
  916,871   38,217,343
OY Nofar Energy Ltd. (Israel)(c)
  750,478   20,078,405
RENOVA, Inc. (Japan)(c)(d)
  1,463,541   21,706,528
Scatec ASA (South Africa)(e)
  2,297,823   23,220,950
Solaria Energia y Medio Ambiente S.A. (Spain)(c)
  2,134,268   49,567,756
Sunnova Energy International, Inc.(c)(d)
  2,635,868   52,717,360
West Holdings Corp. (Japan)(d)
  590,811   21,309,519
Xinyi Energy Holdings Ltd. (China)(d)
  79,602,030   43,831,315
        513,292,772
Mortgage REITs-2.27%
Hannon Armstrong Sustainable Infrastructure Capital, Inc.(d)
  1,353,983   51,546,133
  Shares   Value
Semiconductors & Semiconductor Equipment-61.36%
Canadian Solar, Inc. (Canada)(c)(d)
  1,574,281   $50,471,449
Daqo New Energy Corp., ADR (China)(c)(d)
  2,001,972   97,896,431
Enphase Energy, Inc.(c)
  1,382,388   257,386,822
First Solar, Inc.(c)(d)
  1,900,173   134,171,215
Flat Glass Group Co. Ltd., H Shares (China)(b)(d)
  12,247,224   50,967,983
GCL Technology Holdings Ltd. (China)(c)(d)
  418,956,497   150,589,483
Gigasolar Materials Corp. (Taiwan)
  2,181,000   11,121,034
JinkoSolar Holding Co. Ltd., ADR (China)(b)(c)(d)
  1,506,155   92,282,117
Maxeon Solar Technologies Ltd.(c)(d)
  1,245,124   14,891,683
Meyer Burger Technology AG (Switzerland)(b)(c)(d)
  73,563,590   34,443,002
Motech Industries, Inc. (Taiwan)(b)
  17,017,000   17,295,487
SMA Solar Technology AG (Germany)(d)
  682,786   32,300,162
SolarEdge Technologies, Inc.(c)
  735,585   200,660,232
SunPower Corp.(c)(d)
  2,524,431   44,606,696
TSEC Corp. (Taiwan)(b)(c)
  19,016,000   24,339,170
United Renewable Energy Co. Ltd. (Taiwan)(c)
  50,177,458   36,822,734
Xinyi Solar Holdings Ltd. (China)
  80,233,868   142,968,877
        1,393,214,577
TOTAL INVESTMENTS IN SECURITIES

(excluding investments purchased with cash collateral from securities on loan)-99.95%

(Cost $2,761,616,342)
  2,269,648,647
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-24.65%
Invesco Private Government Fund, 0.74%(b)(f)(g)
  167,889,832   167,889,832
Invesco Private Prime Fund, 0.87%(b)(f)(g)
  391,703,771   391,742,949
Total Investments Purchased with Cash Collateral from Securities on Loan

(Cost $559,565,936)
  559,632,781
TOTAL INVESTMENTS IN SECURITIES-124.60%

(Cost $3,321,182,278)
  2,829,281,428
OTHER ASSETS LESS LIABILITIES-(24.60)%
  (558,580,440)
NET ASSETS-100.00%
  $2,270,700,988
    
See accompanying notes which are an integral part of this schedule.
Invesco Solar ETF (TAN)—(continued)
May 31, 2022
(Unaudited)
Investment Abbreviations:
ADR -American Depositary Receipt
REIT -Real Estate Investment Trust
    
Notes to Schedule of Investments:
(a) Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b) Affiliated issuer. The issuer is affiliated by having an investment adviser that is under common control of Invesco Ltd. and/or the Investment Company Act of 1940, as amended (the “1940 Act”), defines “affiliated person” to include an issuer of which a fund holds 5% or more of the outstanding voting securities. The Fund has not owned enough of the outstanding voting securities of the issuer to have control (as defined in the 1940 Act) of that issuer. The table below shows the Fund’s transactions in, and earnings from, its investments in affiliates for the nine months ended May 31, 2022.
    
  Value
August 31, 2021 		  Purchases
at Cost 		  Proceeds
from Sales 		  Change in
Unrealized
Appreciation
(Depreciation) 		  Realized
Gain
(Loss) 		  Value
May 31, 2022 		  Dividend
Income
Investments in Affiliated Money Market Funds:                          
Invesco Government & Agency Portfolio, Institutional Class $22,392,028   $117,658,460   $(140,050,488)   $-   $-   $-   $1,333
Investments Purchased with Cash Collateral from Securities on Loan:                          
Invesco Private Government Fund 248,743,131   722,546,309   (803,399,608)   -   -   167,889,832   213,845*
Invesco Private Prime Fund 581,927,213   1,511,273,534   (1,701,308,949)   66,840   (215,689)   391,742,949   713,670*
Investments in Other Affiliates:                          
Anji Technology Co. Ltd. 9,755,635   -   (8,186,704)   5,725,615   (7,294,546)   -   -
Beam Global*** 12,568,322   11,132,094   (13,900,132)   6,105,562   (15,905,846)   -   -
Luoyang Glass Co. Ltd., H Shares** 31,425,445   9,606,405   (21,120,174)   (8,440,349)   6,137,043   17,608,370   -
Motech Industries, Inc.** 24,899,702   11,639,507   (19,084,946)   2,915,603   (3,074,379)   17,295,487   -
Sunworks Inc 11,990,259   6,174,372   (9,561,308)   8,325,754   (16,929,077)   -   -
TSEC Corp.** 28,150,071   15,094,393   (24,654,548)   6,818,482   (1,069,228)   24,339,170   -
Total $971,851,806   $2,405,125,074   $(2,741,266,857)   $21,517,507   $(38,351,722)   $618,875,808   $928,848
    
* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.
** As of May 31, 2022, this security was not considered as an affiliate of the Fund.
*** As of August 31, 2021, this security was not considered as an affiliate of the Fund.
    
(c) Non-income producing security.
(d) All or a portion of this security was out on loan at May 31, 2022.
(e) Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be resold pursuant to an exemption from registration under the 1933 Act, typically to qualified institutional buyers. The aggregate value of these securities at May 31, 2022 was $61,438,293, which represented 2.71% of the Fund’s Net Assets.
(f) The rate shown is the 7-day SEC standardized yield as of May 31, 2022.
(g) The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return of the securities loaned.  
    
This Fund has holdings greater than 10% of net assets in the following country:  
China 27.81%
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Notes to Quarterly Schedules of Portfolio Holdings
May 31, 2022
(Unaudited)
NOTE 1—Additional Valuation Information
Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available or are unreliable. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment’s assigned level:
Level 1 — Prices are determined using quoted prices in an active market for identical assets.
Level 2 — Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others.
Level 3 — Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect a Fund’s own assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.
The following is a summary of the tiered valuation input levels, as of May 31, 2022, for each Fund (except for PHLX Semiconductor ETF). As of May 31, 2022, all of the securities in PHLX Semiconductor ETF were valued based on Level 1 inputs (see the Schedules of Investments for security categories). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.
  Level 1   Level 2   Level 3   Total
Invesco Nasdaq Biotechnology ETF              
Investments in Securities              
Common Stocks & Other Equity Interests $23,671,558   $-   $-   $23,671,558
Money Market Funds -   3,579,246   -   3,579,246
Total Investments $23,671,558   $3,579,246   $-   $27,250,804
Invesco Solar ETF              
Investments in Securities              
Common Stocks & Other Equity Interests $2,269,648,647   $-   $-   $2,269,648,647
Money Market Funds -   559,632,781   -   559,632,781
Total Investments $2,269,648,647   $559,632,781   $-   $2,829,281,428
A reconciliation of Level 3 investments is presented when a Fund had a significant amount of Level 3 investments at the beginning and/or end of the reporting period in relation to net assets.
The following is a reconciliation of the fair valuations using significant unobservable inputs (Level 3) during the period ended May 31, 2022:
  Value
08/31/21 		  Purchases
at Cost 		  Proceeds
from Sales 		  Accrued
Discounts/
Premiums 		  Realized
Gain (Loss) 		  Change in
Unrealized
Appreciation
(Depreciation) 		  Transfers
into
Level 3* 		  Transfers
out of
Level 3* 		  Value
05/31/22
Solar ETF                                  
Common Stocks & Other Equity Interests $44,976,464   $-   $(56,209,102)   $–   $38,905,753   $(27,673,115)   $–   $-   $-